RTTNews | Aug 25, 2020 07:45AM EDT

07:45 Tuesday, August 25, 2020 (RTTNews.com) - Mereo BioPharma Group plc (MREO) announced the initiation of a phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease. The trial will be conducted at the University of Alabama. The primary endpoint of the trial is safety and tolerability of alvelestat at day 10, with a safety follow up to day 90.

Alvelestat is an oral small molecule designed to inhibit neutrophil elastase, a key enzyme involved in the destruction of lung tissue.

Read the original article on RTTNews ( https://www.rttnews.com/3123672/mereo-begins-phase-1b-2-trial-to-evaluate-alvelestat-in-covid-19-associated-respiratory-disease.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved